摘要
背景:新一代抗抑郁药(NGAS)是临床医生在抗抑郁斗争中的最新武器。选择性5-羟色胺再摄取抑制剂的引入(SSRIs),大量的其他组随后,确定了其主要的活性机制:5-羟色胺和去甲肾上腺素再摄取抑制剂(SNRI);5-羟色胺调节剂和刺激剂(SMS);SER。羟色胺拮抗剂和再摄取抑制剂(SARI);去甲肾上腺素能和选择性5-羟色胺能抗抑郁药(NASA);去甲肾上腺素再摄取抑制剂(NERI);5-羟色胺、去甲肾上腺素和多巴胺rE摄取抑制剂(SNDRI)或三重摄取抑制剂(TRI);褪黑素和5-羟色胺激动剂(MASA)。虽然SSRIs仍然是应用最广泛和最著名的NGA,但其他的集团是Inc。在目前的治疗环境中重新使用,可以获得类似的临床结果,并且具有耐受性和安全性,这通常比SS具有显著的优势。arisadvanced range instrumentation ships 高级靶场仪器船,导弹靶场仪器船 方法:检索Scopus和PubMed数据库中最重要的文献,包括药物化学、药效学、药代动力学和人体体液中的分析。e以下抗抑郁药:文拉法辛、度洛西汀、米拉西坦、曲唑酮、伏蒂奥西汀、维拉唑酮。 结果:描述了非SSRI nga(属于snri、sari和sms类)的主要特点,重点介绍了可应用于以下方面的分析方法的作用:执行治疗药物监测(TDM),但也包括药物的药动学,代谢和相互作用。
关键词: 分析,化学-临床相关性,药物-药物相互作用,代谢,药理特性,新一代抗抑郁药(NGAS),治疗药物监测(TDM)。
Current Medicinal Chemistry
Title:New-Generation, Non-SSRI Antidepressants: Therapeutic Drug Monitoring and Pharmacological Interactions. Part 1: SNRIs, SMSs, SARIs
Volume: 25 Issue: 7
关键词: 分析,化学-临床相关性,药物-药物相互作用,代谢,药理特性,新一代抗抑郁药(NGAS),治疗药物监测(TDM)。
摘要: Background: New-generation antidepressants (NGAs) are the latest additions to the clinician’s arsenal in the fight against depression. After the introduction of selective serotonin reuptake inhibitors (SSRIs), a plethora of other groups followed, identified by their main mechanisms of activity: serotonin and norepinephrine reuptake inhibitors (SNRI); serotonin modulators and stimulators (SMS); serotonin antagonists and reuptake inhibitors (SARI); noradrenergic and selective serotonergic antidepressants (NaSSA); norepinephrine reuptake inhibitors (NeRI); serotonin, norepinephrine and dopamine reuptake inhibitors (SNDRI) or triple reuptake inhibitors (TRI); and melatonin and serotonin agonists (MaSA). Although SSRIs are still the most widely used and well known NGAs, the other groups are increasingly being used in the current therapeutic settings obtaining comparable clinical results, and with tolerability and safety profiles that can often provide significant advantages over those of SSRIs.
Methods: Scopus and PubMed databases were searched for the most significant papers centered on the medicinal chemistry, pharmacodynamics, pharmacokinetics and analysis in human biological fluids of the following antidepressants: venlafaxine, duloxetine, milnacipran, trazodone, vortioxetine, vilazodone.
Results: The main characteristics of commercially available non-SSRI NGAs (belonging to the SNRI, SARI and SMS classes) are described, focusing on the role of analytical methods that can be applied to perform therapeutic drug monitoring (TDM), but also including drug pharmacokinetics, metabolism and interactions.
Export Options
About this article
Cite this article as:
New-Generation, Non-SSRI Antidepressants: Therapeutic Drug Monitoring and Pharmacological Interactions. Part 1: SNRIs, SMSs, SARIs, Current Medicinal Chemistry 2018; 25 (7) . https://dx.doi.org/10.2174/0929867324666170712165042
DOI https://dx.doi.org/10.2174/0929867324666170712165042 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial:Polypharmacology of Natural Products
Mini-Reviews in Organic Chemistry Serum Biochemical Markers of Brain Injury
Mini-Reviews in Medicinal Chemistry Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors
Current Pharmaceutical Design Cardiopulmonary Interactions in Children with Heart Failure
Current Cardiology Reviews CB Receptor Ligands from Plants
Current Topics in Medicinal Chemistry Non-IgE Mediated Food Allergy
Inflammation & Allergy - Drug Targets (Discontinued) Antioxidant Properties of Crocus Sativus L. and Its Constituents and Relevance to Neurodegenerative Diseases; Focus on Alzheimer’s and Parkinson’s Disease
Current Neuropharmacology Docking, Synthesis and Anti-Diabetic Activity of Novel Sulfonylhydrazone Derivatives Designed as PPAR-Gamma Agonists
Current Topics in Medicinal Chemistry Update in Pharmacological Management of Coronary No-Reflow Phenomenon
Cardiovascular & Hematological Agents in Medicinal Chemistry Vcsa1 Gene Peptides for the Treatment of Inflammatory and Allergic Reactions
Recent Patents on Inflammation & Allergy Drug Discovery Methylene Blue not Contraindicated in Treating Hemodynamic Instability in Pediatric and Neonate Patients
Current Pediatric Reviews Corticosteroids in Sepsis: Pathophysiological Rationale and the Selection of Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Novel Approach to Cardiovascular Diseases: A Promising Probability of (Pro)Renin Receptor [(P)RR]
Current Pharmaceutical Design Polypharmacy in Cardiovascular Medicine: Problems and Promises!
Cardiovascular & Hematological Agents in Medicinal Chemistry Inhibitory Effect of PD-1/PD-L1 and Blockade Immunotherapy in Leukemia
Combinatorial Chemistry & High Throughput Screening Blockade of Renin Angiotensin System in Heart Failure Post-Myocardial Infarction: What is the Best Therapy?
Recent Patents on Cardiovascular Drug Discovery Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Why is the Inhibition of the Renin-Angiotensin System Effective for Preventing Cardiac Events in Patients with Coronary Risk Factors or Coronary Artery Disease?
Current Cardiology Reviews Minoxidil Use in Dermatology, Side Effects and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery